Загрузка...
Developing pharmacological therapies for Alzheimer disease
Alzheimer disease (AD), while chronic and progressive with an average progression of 7–10 years, is both multifactorial and heterogeneous. Thus, AD offers a large window of opportunity and a large number of therapeutic targets to inhibit it. The selection of a therapeutic target, however, is one of...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2007
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3139452/ https://ncbi.nlm.nih.gov/pubmed/17604997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00018-007-7221-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|